Late-Onset Hypogonadism
Age-Related Testosterone Decline and the Contested Term 'Andropause'
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not an FDA-recognized indication for TRT
Reference only. Not medical advice.
What can go wrong
Treating age-related decline as a disease drives testosterone prescribing to men who do not meet diagnostic thresholds. The 2015 FDA action specifically restricted testosterone labeling to hypogonadism from underlying medical conditions, NOT age-related decline, precisely because the latter lacks demonstrated benefit-to-risk justification for the broad population being marketed to.
This is something to take to a clinician. The Atlas can tell you what is known about late-onset hypogonadism in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Testosterone declines gradually with age, roughly 1-2% per year after age 30 in healthy men (European Male Aging Study, EMAS). 'Andropause' and 'male menopause' are marketing-friendly terms implying an abrupt, universal hormonal cliff analogous to female menopause. Endocrinologists contest the term: there is no sharp cessation of gonadal function, the decline is slow and variable, and much of the drop tracks with weight gain, illness, and poor sleep rather than aging alone. The EMAS defined late-onset hypogonadism narrowly, requiring three sexual symptoms PLUS total testosterone below 320 ng/dL, and found it affects only about 2% of men aged 40-79.
There is no male equivalent of menopause, and the word that implies otherwise sells testosterone.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Aging reduces testosterone through multiple converging mechanisms: declining Leydig cell number and responsiveness, blunted GnRH/LH pulse amplitude, and a rise in SHBG that lowers free testosterone faster than total. Comorbidities of aging, visceral adiposity (which raises aromatase), insulin resistance, sleep disruption, and chronic illness, independently suppress the axis, so 'age' is partly a proxy for accumulated metabolic burden.
Why endocrinologists reject 'andropause'
Menopause is a defined, universal, relatively abrupt loss of ovarian function. Male testosterone decline is none of those things: it is gradual, highly variable between men, partially reversible through weight loss and sleep, and absent altogether in many healthy older men. The EMAS data show that when you require both consistent sexual symptoms and biochemically low testosterone, genuine late-onset hypogonadism is uncommon. The term 'andropause' implies inevitability and equivalence to menopause, which the marketplace uses to frame normal aging as a treatable deficiency.
Safety in detail
Age-related symptoms attributed to testosterone are frequently caused by sleep deficiency, obesity, depression, medication, or chronic illness. Evaluation by a qualified physician is required before attributing symptoms to low testosterone or initiating therapy, which carries documented health risks.
What it does to fertility
Older men considering therapy for age-related decline still face full HPG suppression and impaired spermatogenesis from exogenous testosterone, relevant for the subset still seeking fertility.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Two morning total testosterone measurements
- Free testosterone and SHBG
- Symptom assessment (sexual symptoms most specific)
- Screening for reversible contributors: weight, sleep apnea, depression, medications
What people get wrong
Often saidAndropause is the male menopause
ActuallyThere is no abrupt, universal cessation of gonadal function in men. Age-related decline is gradual, variable, and partly reversible; 'andropause' is a marketing construct, not a clinical diagnosis.
Often saidFalling energy after 40 means you need testosterone
ActuallyFatigue and mood symptoms have many causes; in EMAS, only a small minority of men with such symptoms had biochemically confirmed hypogonadism.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Decline rate
- ~1-2%/year after 30
- EMAS LOH prevalence
- ~2% (40-79 yrs)
- EMAS definition
- 3 sexual symptoms + T < 320 ng/dL
- 'Andropause' status
- Contested, non-clinical
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Late-Onset Hypogonadism. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
European Male Aging Study (EMAS, Wu et al.)2010
Defined late-onset hypogonadism by combined symptom + biochemical criteria; prevalence ~2% in men 40-79
New England Research Institutes / Travison et al.2007
Documented ~1%/year per-cohort population decline beyond individual aging